Factors associated with dyslipidemia in Chinese patients with uncomplicated hypertension were investigated in 1139 patients who were newly prescribed a single antihypertensive drug in the public primary healthcare setting in Hong Kong, where their fasting lipid profiles were measured 4-16 weeks after the first prescription. Multivariate logistic regression showed that thiazide users were more likely (odds ratio (OR) 3.67, 95% CI 1.13, 11.88, P ¼ 0.030) to have adverse (X6.2 mmol/l) total cholesterol (TC) compared with drugs acting on the renin angiotensin system (RAS), but the absolute difference in mean TC between thiazide users and all patients was small (0.14 mmol/l), whereas advanced age and male gender were also associated with some aspects of dyslipidemia. Clinicians should be aware of the increased risk of dyslipidemia in these groups, but the mild dyslipidemic profile associated with thiazides should not in itself deter its use as a possible first-line antihypertensive agent among Chinese patients.
Dyslipidemia has been recognized as a strong predictor of cardiovascular disease. 1 There is increasing evidence that dyslipidemia is associated with 2 and possibly a causative factor in hypertension. 3 Studies on the potential predictive factors of dyslipidemia among established hypertensive patients are few, and evidence on the possible relationship between antihypertensive drug classes and dyslipidemia is mixed. 4, 5 To our knowledge there are few reports on the risk factors of dyslipidemia among hypertensive patients of Chinese ethnicity. This study examined the lipid profiles of Chinese hypertensive patients who were newly prescribed a single antihypertensive agent and evaluated the risk association between potential predictive factors and the occurrence of dyslipidemia.
We retrieved data from the clinical database of the Hospital Authority, Hong Kong that consists of patient demographics, clinical diagnoses, prescription details and laboratory investigation results in every out-patient consultation. Previous evaluations of this clinical tool for research purposes 6 X2.3 mmol/l), low-density lipoprotein-cholesterol (LDL-C) (o2.6; 2.6-4.0; X4.1 mmol/l) and highdensity lipoprotein-cholesterol (HDL-C) (X1.5; 1.0-1.5; o1.0 mmol/l) by each major drug class. Lipid profiles were measured after an overnight fast of 8-12 h. LDL-C was calculated using the Friedewald formula 7 but direct LDL-C was measured instead where TG level was X4.5 mmol/l. Student's t-tests were used for comparison of continuous variables whereas w 2 tests were used for categorical variables. Separate unconditional binary logistic regression analyses for each lipid parameter (TC, triglyceride (TG), LDL-C and HDL-C) were conducted. Independent predictors and covariates included patient age, gender, patient's payment status (fee-waivers vs payers), district of residence, types of clinics attended (general vs family medicine specialist vs staff clinics) and the antihypertensive drug classes prescribed (thiazide diuretics, b-blockers, calcium channel blockers (CCB) and RAS-modifiers). Above borderline lipid profiles were defined as, respectively, TCX5.2 mmol/l; TGX1.7 mmol/l; LDL-C X2.6 mmol/l; less than optimal for HDL-C defined as p1.6 mmol/l; Adverse results were defined as TC X6.2 mmol/l; TG X2.3 mmol/l; LDL-C X4.1 mmol/l; HDL-Cp1.0 mmol/l. b None of the patients had adverse HDL-cholesterol readings. All adjusted ORs were adjusted for age, gender, payment status, district of residence, service types of attended clinics and drug classes as listed in table.
There were 1139 eligible patients with a mean age of 61 years, 59.3% of whom were females in the sample (Supplementary file 2) . Among the four drug classes, thiazide users had the highest mean values of TC (5.38 mmol/l) and TG (1.59 mmol/l), CCB users had highest levels of LDL-C (3.22 mmol/l) and b-blockers users had the lowest levels of HDL-C (1.52 mmol/l). These apparent differences in lipid parameters between drug groups were statistically insignificant (P ¼ 0.265 to 0.881). For all lipid parameters, the crude differences in proportion of patients with adverse lipid profiles among the various drug classes did not reach statistical significance either (P ¼ 0.213 to 0.951) (Supplementary file 3). From multivariate regression analyses, thiazide users were 3.67 times more likely than RAS to show adverse TC levels (OR 3.670, 95% C.I. 1.134, 11.876, P ¼ 0.030) ( Table 1 ). However, the absolute difference between mean TC between thiazide users and all patients was only 0.14 mmol/l. When compared with younger age groups, advanced age (X50 years) was found to be positively associated with borderline high TC (OR 1.513-1.788, P ¼ 0.015 to 0.057) and high TC (OR 2.493-2.834, P ¼ 0.002 to 0.016) but negatively associated with HDL-C (OR 0.523-0.626, P ¼ 0.013 to 0.042) ( Table 1) . Male patients were also more likely to have less than optimal HDL-C (OR 2.535, Po0.001).
Thiazide diuretics have been shown to increase levels of TC and LDL-C by 5-7% without alteration of HDL-C in the first year of antihypertensive treatment, 8 while other studies reported a decline in lipid profiles with use of diuretics. 9 Our finding that thiazides are positively associated with adverse TC levels implies association with hypercholesterolemia in Chinese hypertensive patients, noting that the absolute increase in TC levels was relatively mild and comparable to Kasiske et al.'s study 10 which reported a similar difference in mean TC (0.12 mmol/l) between thiazide users and other antihypertensive drug classes.
Published studies on the association of age and gender with dyslipidemia are inconclusive. Increased serum cholesterol was found with increasing age by Kesteloot et al. 11 Cai et al. 12 reported a rise in HDL-C with age in men only and with decreasing concentrations in women after age 50. In this study both age and gender were associated with dyslipidemia, which may represent a new finding among ethnic Chinese.
Some limitations of this study should be mentioned. First, the lack of baseline lipid profiles, which could act as reference values prevents beforeafter exposure comparisons of lipid levels. Also, we recognize the absence of ICPC coding which more accurately excludes the presence of relevant comorbidities. Secondly, this study cannot prove causative relationships between predictor variables and lipid profiles, which can only be addressed through a prospective cohort design.
In conclusion, in the present study on Chinese subjects, thiazide use was associated with elevated cholesterol levels, but the absolute increase in TC was small. Increasing age and male gender were also associated with increased risk of dyslipidemia. Clinicians should be aware of these increased risks, but the mild dyslipidemic profile associated with thiazides should not in itself deter its use as a possible first-line antihypertensive agent among Chinese patients. 
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